Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Gamma-delta (γδ) T cells contribute to the innate immune response against cancer. In samples of 20 patients upon DLBCL diagnosis, we found that Vδ1 T cells were the major γδ T cell subset in tumors and PBMCs of patients, while Vδ2 T cells were preponderant in PBMCs of healthy subjects. Interestingly, the germinal center (GC) subtype was associated with an increase in Vδ1 T cells in tumors, whereas the non-GC subtype was associated with a lower frequency of γδ T cells. While circulating Vδ1 T cells of patients or HSs mostly exhibited a naïve phenotype, the majority of tumor Vδ1 T cells showed a central memory phenotype. Resident or circulating γδ T cells from patients were not functionally impaired since they produced high levels of IFN-γ. Collectively, our findings are in favor of γδ T cell activation in tumors and open new perspectives for their modulation in DLBCL immunotherapy.

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2017.1321751DOI Listing

Publication Analysis

Top Keywords

vδ1 cells
20
cells patients
12
γδ cells
12
cells
9
γδ cell
8
subtype associated
8
vδ1
5
patients
5
γδ
5
increased frequencies
4

Similar Publications

Impact of mistletoe lectin binding in breast cancer.

Anticancer Res

June 2004

Zentrum für diagnostische Medizin Robert Bosch Krankenhaus, Auerbachstr. 110, D-70376 Stuttgart, Germany.

Background: One of the most often used complementary or alternative anticancer therapeutics for breast cancer is mistletoe extract with Viscum album lectin (VAA-1) as the leading component. The aim of this study was to determine the correlation between VAA-1 binding in breast cancer and disease outcome.

Materials And Methods: VAA-1 binding to either tumour cells or tumour infiltrating inflammatory cells was examined by immunohistochemical staining of paraffin tissue sections from breast cancer patients (n=226).

View Article and Find Full Text PDF

Combined cytotoxic action of Viscum album agglutinin-1 and anticancer agents against human A549 lung cancer cells.

Anticancer Res

December 2001

Dr. Margarete Fischer-Bosch-Institut für Klinische Pharmakologie, Stuttgart, Germany.

Background: Viscum album agglutinin-1 (VAA-1) is assumed to be the biologically most active ingredient of misteltoe extracts that are often used as adjuvant cancer therapy. To develop new approaches for lung cancer treatment, we evaluated the antineoplastic activity of VAA-1 alone and in combination with other chemotherapeutic drugs, including doxorubicin, cisplatin and taxol in the human lung carcinoma cell line A549.

Materials And Methods: Cytotoxicity was determined by 5-bromo-2'-deoxyuridine (BrdU) ELISA-assays and drug interaction assessed by the isobologram method.

View Article and Find Full Text PDF

Modulating activity of mistletoe lectins 1 and 2 on the lymphatic system in BALB/c-mice.

Phytomedicine

January 1996

Institute of Medicinal Microbiology and Hygiene, University of Cologne, D-50935 Cologne, Goldenfelsstr. 19-21.

The galactoside-specific lectin (mistletoe lectin-1, VAA-1) and the N-acetylgalactosamine-specific lectin (mistletoe lectin-2, VAA-2) were purified from aqueous mistletoe extract and checked for their immunoactive potency. Regular subcutaneous administration of the optimal immunomodulating VAA-1 /VAA-2 dosage (1 ng lectin/kg body weight) could be shown to modulate thymocyte proliferation, maturation, emigration and activation in BALB/c-mice. Thus, the increase in thymocyte counts was statistically significant after VAA-1 treatment.

View Article and Find Full Text PDF